Impact of Caspase-8 (CASP8) -652 6N Del and D302H Polymorphisms on Prostate Cancer in Different Ethnic Groups

  • Zhang, Cheng-Dong (Medical Scientific Research Center, Guangxi Medical University) ;
  • Li, Hong-Tao (Medical Scientific Research Center, Guangxi Medical University) ;
  • Liu, Kun (Department of Gastroenterology, The Third Hospital of Nanchang City) ;
  • Lin, Zhi-Di (Department of Urology, Affiliated Hospital of Youjiang Medical College for Nationalities) ;
  • Peng, Qi-Liu (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • Qin, Xue (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University) ;
  • He, Min (Medical Scientific Research Center, Guangxi Medical University) ;
  • Wu, Hua (Medical Scientific Research Center, Guangxi Medical University) ;
  • Mo, Zeng-Nan (Department of Urology, First Affiliated Hospital of Guangxi Medical University) ;
  • Yang, Xiao-Li (Medical Scientific Research Center, Guangxi Medical University)
  • Published : 2014.10.11


Background: Despite evidence suggesting roles for caspase-8 (CASP8) -652 6N del and D302H polymorphisms in prostate cancer (PCa), the association of these polymorphisms with PCa risk remains inconclusive. Therefore, a meta-analysis was performed to more precisely estimate the association of CASP8 -652 6N del and D302H polymorphisms with PCa susceptibility. Materials and Methods: A comprehensive literature search was conducted to identify all case-control studies of CASP8 D302H and -652 6N del polymorphisms and PCa risk. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the association and the precision of the estimate, respectively. Results: Nine -625 6N del studies and 4 D302H studies were included. CASP8 -652 6N del and D302H polymorphisms were not significantly associated with PCa risk in the overall analyses. However, in the subgroup analysis stratified by ethnicity, -625 6N del was significantly associated with PCa risk in the East Asian and Indian populations under the recessive model. Furthermore, the subgroup analysis strongly suggested that D302H was associated with lower PCa risk in the Non-Indian population under the dominant model. Conclusions: In our meta-analysis, ethnic-specific differences were evident in the association of CASP8-625 6N del and D302H polymorphisms with PCa risk.


  1. Benjamini Y, Hochberg Y (1995). Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J Royal Statistical Society, 57, 11.
  2. Bethke L, Sullivan K, Webb E, et al (2009). CASP8 D302H and meningioma risk: an analysis of five case-control series. Cancer Lett, 273, 312-5.
  3. Cybulski. C, Wokolorczyk. D, Gliniewicz. B (2007). A sixnucleotide deletion in the CASP8 promoter is not associated with a susceptibility to breast and prostate cancers in the Polish population. Breast Cancer Res Treat, 112, 367-368.
  4. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
  5. Frank B, Rigas SH, Bermejo JL, et al (2008). The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study. Breast Cancer Res Treat, 111, 139-44.
  6. Fu G, Tang J, Wang M, et al (2011). CASP8 promoter polymorphism, mRNA expression and risk of prostate cancer among Chinese men. J Biomed Res, 25, 128-34.
  7. George GP, Mandal RK, Kesarwani P, et al (2010). Polymorphisms and haplotypes in caspases 8 and 9 genes and risk for prostate cancer: a case-control study in cohort of North India. Urol Oncol, 30, 781-9.
  8. Ho PK, Hawkins CJ (2005). Mammalian initiator apoptotic caspases. FEBS J, 272, 5436-53.
  9. Haiman CA, Garcia RR, Kolonel LN, et al (2008). A promoter polymorphism in the CASP8 gene is not associated with cancer risk. Nat Genet, 40, 259-60.
  10. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
  11. Hirschhorn JN, Lohmueller K, Byrne E, et al (2002). A comprehensive review of genetic association studies. Genet Med, 4, 45-61.
  12. Holm S (1979). A simple sequentially rejective multiple test procedure. Scandinavian J Statistics, 6, 65-70.
  13. Kesarwani P, Mandal RK, Maheshwari R, et al (2011). Influence of caspases 8 and 9 gene promoter polymorphism on prostate cancer susceptibility and early development of hormone refractory prostate cancer. BJU Int, 107, 471-6.
  14. Klein LT, Lowe FC (1997). The effects of prostatic manipulation on prostate-specific antigen levels. Urol Clin North Am, 24, 293-7.
  15. Li YY, Wang XM, Lu XZ (2014). KCNQ1 rs2237892 C-->T gene polymorphism and type 2 diabetes mellitus in the Asian population: a meta-analysis of 15,736 patients. J Cell Mol Med, 18, 274-82.
  16. Lubahn J, Berndt SI, Jin CH, et al (2010). Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. Prostate, 70, 646-53.
  17. MacPherson G, Healey CS, Teare MD, et al (2004). Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst, 96, 1866-9.
  18. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  19. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
  20. Meyer A, Coinac I, Bogdanova N, et al (2013). Apoptosis gene polymorphisms and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy. Urol Oncol, 31, 74-81.
  21. Michailidou K, Hall P, Gonzalez-Neira A, et al (2013). Largescale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet, 45, 353-61.
  22. Sergentanis TN, Economopoulos KP (2010). Association of two CASP8 polymorphisms with breast cancer risk: a metaanalysis. Breast Cancer Res Treat, 120, 229-34.
  23. Son JW, Kang HK, Chae MH, et al (2006). Polymorphisms in the caspase-8 gene and the risk of lung cancer. Cancer Genet Cytogenet, 169, 121-7.
  24. Sun T, Gao Y, Tan W, et al (2007). A six-nucleotide insertiondeletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet, 39, 605-13.
  25. Turnbull C, Ahmed S, Morrison J, et al (2010). Genomewide association study identifies five new breast cancer susceptibility loci. Nat Genet, 42, 504-7.
  26. Wu Z, Li Y, Li S, et al (2013). Association between main Caspase gene polymorphisms and the susceptibility and prognosis of colorectal cancer. Med Oncol, 30, 565.
  27. Zhao CX, Liu M, Wang JY, et al (2013). Association of 8 loci on chromosome 8q24 with prostate carcinoma risk in northern Chinese men. Asian Pac J Cancer Prev, 14, 6733-8.
  28. Zheng SL, Sun J, Wiklund F, et al (2008). Cumulative association of five genetic variants with prostate cancer. N Engl J Med, 358, 910-9.
  29. Zhou X, Gu Y, Zhang SL (2012). Association between p53 codon 72 polymorphism and cervical cancer risk among Asians: a HuGE review and meta-analysis. Asian Pac J Cancer Prev, 13, 4909-14.

Cited by

  1. Shorter GGN Repeats in Androgen Receptor Gene Would Not Increase the Risk of Prostate Cancer vol.16, pp.2, 2017,
  2. and the Risk of Prostate Cancer pp.1533-0338, 2017,